CN104800831B - 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 - Google Patents
寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 Download PDFInfo
- Publication number
- CN104800831B CN104800831B CN201410033350.8A CN201410033350A CN104800831B CN 104800831 B CN104800831 B CN 104800831B CN 201410033350 A CN201410033350 A CN 201410033350A CN 104800831 B CN104800831 B CN 104800831B
- Authority
- CN
- China
- Prior art keywords
- lys
- phe
- gly
- sqffglm
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229960000482 pethidine Drugs 0.000 title claims abstract description 23
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 20
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 16
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 33
- 229940079593 drug Drugs 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 description 37
- 239000007924 injection Substances 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 238000000185 intracerebroventricular administration Methods 0.000 description 23
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 17
- 102100039365 Tachykinin-4 Human genes 0.000 description 17
- 102000003840 Opioid Receptors Human genes 0.000 description 16
- 108090000137 Opioid Receptors Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 14
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 14
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 14
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 14
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 101000669528 Homo sapiens Tachykinin-4 Proteins 0.000 description 12
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 11
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 11
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 229940127557 pharmaceutical product Drugs 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 102100024622 Proenkephalin-B Human genes 0.000 description 9
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 9
- 108010074732 preproenkephalin Proteins 0.000 description 9
- 108020001588 κ-opioid receptors Proteins 0.000 description 9
- 102100038931 Proenkephalin-A Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108010041071 proenkephalin Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102100024304 Protachykinin-1 Human genes 0.000 description 5
- 101710149435 Tachykinin-4 Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 108010041634 preprotachykinin Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102100037346 Substance-P receptor Human genes 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000035611 feeding Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 101800000399 Neurokinin A Proteins 0.000 description 3
- 102400000097 Neurokinin A Human genes 0.000 description 3
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 3
- 102000046798 Neurokinin B Human genes 0.000 description 3
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 3
- 101800002813 Neurokinin-B Proteins 0.000 description 3
- 102000001490 Opioid Peptides Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 239000003399 opiate peptide Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 102100028647 Mu-type opioid receptor Human genes 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 108070000021 Opioid peptides receptors Proteins 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000146 antalgic effect Effects 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- -1 MOR Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101500025123 Mus musculus Hemokinin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000009493 Neurokinin receptors Human genes 0.000 description 1
- 108050000302 Neurokinin receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101500025128 Rattus norvegicus Hemokinin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 239000000841 delta opiate receptor agonist Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410033350.8A CN104800831B (zh) | 2014-01-23 | 2014-01-23 | 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410033350.8A CN104800831B (zh) | 2014-01-23 | 2014-01-23 | 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104800831A CN104800831A (zh) | 2015-07-29 |
CN104800831B true CN104800831B (zh) | 2018-09-21 |
Family
ID=53686309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410033350.8A Active CN104800831B (zh) | 2014-01-23 | 2014-01-23 | 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104800831B (zh) |
-
2014
- 2014-01-23 CN CN201410033350.8A patent/CN104800831B/zh active Active
Non-Patent Citations (3)
Title |
---|
Effects of rat/mouse hemokinin-1, a mammalian tachykinin peptide,on the antinociceptive activity of pethidine administered at the peripheral and supraspinal level.;Cai-Yun Fu et al.;《Behavioural Brain Research》;20070619;39-46 * |
Hemokinins and endokinins;N.M.Page;《Cellular and Molecular Life Sciences》;20041231;1652-1663 * |
In vivo characterization of the effects of human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on the modulation of pain in mice;Cai Y. Fu et al.;《Brain, Behavior, and Immunity》;20080208;850-860 * |
Also Published As
Publication number | Publication date |
---|---|
CN104800831A (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Zoledronic acid promotes TLR‐4‐mediated M1 macrophage polarization in bisphosphonate‐related osteonecrosis of the jaw | |
JP2023036871A (ja) | 心不全の治療用組成物 | |
McCoy et al. | Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents | |
CN103458916B (zh) | 长效肽类似物 | |
CN111407882A (zh) | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 | |
CN104159594A (zh) | 用于皮肤病治疗的凯莫瑞c15肽的局部制剂 | |
MX2007004676A (es) | Analogos de la hormona adrenocorticotropica y metodos relacionados. | |
BRPI0721259A2 (pt) | composto, composiÇço farmacÊutica, uso de composto, e, processo para a fabricaÇço de composto | |
JP2001247477A (ja) | 抗腫瘍剤 | |
CN101394861A (zh) | 纽兰格林持续给药能改善心脏功能 | |
CN102215859B (zh) | 垂体腺苷酸环化酶激活多肽(pacap)以及pacap类似物作为与抗癌剂一起的辅助治疗的用途 | |
CN106632601B (zh) | 一种阻断突触长时程增强(ltp)的短肽及其应用 | |
JP5427186B2 (ja) | システイン非含有環状タンパク質 | |
Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
WO2017040186A1 (en) | Compositions and methods for the treatment of neurodamage | |
CN104800829B (zh) | 寡肽联合或与吗啡的组合在制备用于镇痛的药物中的用途 | |
CN104800831B (zh) | 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途 | |
CN104800832B (zh) | 一种用于癌痛治疗的寡肽联合或与吗啡组合的产品 | |
CN104800830B (zh) | 一种用于癌痛治疗的寡肽联合或与哌替啶组合的产品 | |
US20210024928A1 (en) | C/ebp alpha sarna compositions and methods of use | |
JP2003509466A (ja) | コルチコトロピン放出ホルモンアナログを使用する異常な細胞増殖の阻害 | |
CN104800835A (zh) | 寡肽联合或与脑啡肽的组合在制备用于镇痛的药物中的用途 | |
CN113201049B (zh) | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 | |
CN104800827A (zh) | 寡肽在制备用于提高delta阿片受体表达的药物中的用途 | |
KR101306157B1 (ko) | 사이클로펜타펩타이드를 유효성분으로 포함하는 종양의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 258, Xueyuan Street, Xiasha Higher Education Park, Hangzhou, Zhejiang 310,000 Patentee after: China Jiliang University Address before: No. 258, Xueyuan Street, Xiasha Higher Education Park, Hangzhou, Zhejiang 310,000 Patentee before: China Jiliang University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: 810000, No. 141 Bayi East Road, Economic and Technological Development Zone, Xining City, Qinghai Province Patentee after: Qinghai ChenFei Pharmaceutical Co.,Ltd. Address before: No. 258, Xueyuan Street, Xiasha Higher Education Park, Hangzhou, Zhejiang 310,000 Patentee before: China Jiliang University |